There are about 1060 potential drug molecules:
ONE of them might be the CURE
In all of history, only 100M molecules have been analyzed. We help you explore the greater universe of molecular combinations, and optimize according to your priorities. Our computational technology is orders of magnitude better than traditional methods, and our process is open and collaborative. We support, coordinate and document projects all the way through to pre-clinical trials.
Everyday Pharma’s master platform brings together independent companies who are developing astonishing innovations in drug discovery, design and development. We add integration, custom applications and a scientific team to chaperone molecules through the workflow. We also provide formatted data for regulatory submittals.
Every project has its own unique priorities and challenges. For example: will you need additional human talent, are you testing off-patent drugs for new indications, can you rely on an existing body of research, what is your risk tolerance, and are you focused on the genome of one individual or seeking a cure for many? Together, we create a project plan to meet your needs.
You may elect to work in our secure environment with IP protection. Or you may invite the world’s leading scientists to participate in a collaborative design, and share your results.
Our projects are FAST. A complete project run costs about 10% of the average overhead for big pharma, so you'll be able to accomplish more with your resources. Select projects may be discounted in exchange for a share of royalties for developed drug candidates. And we have reason to believe our success rate in clinical trials will be substantially higher.
Please contact us if you would like to receive technical documentation, and to discuss a potential project. We look forward to hearing from you.
We continuously search the globe for up-to-the-minute technology improvements in drug discovery, design and development. Our partner companies include two-person engineering startups as well as established firms with years of experience and a successful track record. Partners offer both in and ex silico solutions. For special projects, partners may provide technology customization and advanced technical support.
As a customer of Everyday Pharma, you’ll have access to a comprehensive pharma bench, with ONE payment portal and licensing agreement for all of your drug discovery needs. You will be assigned an experienced project manager to assist you with the selection of partner companies best suited to yield the results you are seeking.
If you are interested in joining us as a technology partner, please contact:
Everyday Pharma is powered by expert advice, skills and talent, from industry leaders in pharma and technology:
Former Vice President, External Innovation, Sanofi, with 23 years of experience in pharma. Specialties: Scouting Biotechs, Life Science, Digital Health, Nanotechnologies.
Board-certified clinical pathologist and experienced molecular diagnostics executive. Doug has been a founder and senior executive in numerous biotechnology and personalized medicine companies including Nichols Specialty Laboratories, OncorMed, GeneLogic and Veracyte.
Former Director of Science, Synthego, former VP Research and Development Halcyon Molecular, and Cofounder, Health Extension.
Former Senate Majority Leader, physician, heart and lung transplant surgeon, serves on the board of the Robert Wood Johnson Foundation, Kaiser Family Foundation, and Harvard Medical School.
Former Director for Global Innovation Management and Strategy at Boehringer Ingelheim with over 25 years of experience in healthcare and life sciences. Stephan is currently CEO, German Institute for Telemedicine and Health Promotion (DITG).
Fellow at Stanford University’s Center of the Molecular Analysis and Design, formerly Technology and Business Development for Now Labs, Inc., holds an B.A. and a M.Sci. in Chemistry from the University of Cambridge in the UK and a PhD in Neuroscience from the Rockefeller University.
Flo manages the software development efforts within the Bio/Nano/Programmable Matter Research Group at Autodesk. His areas of expertise include software architecture, cloud technologies, software development process and bionanotechnology. Florencio received a M.Sc. in Information Networking from Carnegie Mellon University in 1999 and a B.Sc. in Systems Analysis from the Universidad de Buenos Aires in 1995.
Founding Partner and Former CEO at San Francisco based innovation practice, Now Labs, assisting science and technology startups with market strategy and implementation, including production of digital assets and media campaigns, fundraising and business development.
Operates his own freelance practice in San Francisco. Previously, he worked for top digital agencies in London and Stockholm, designing web campaigns and brand identities, and served as Creative Director for a 2-time Webby award-winning online and print magazine.
PhD candidate in Computational Biology and Bioinformatics program at Duke University working under the supervision of Dr. David Beratan. His research interest is in the area of molecular design and property optimization, molecular modeling, and machine learning. Prior to joining Duke University, he graduated from Hampden-Sydney College with a Phi Beta Kappa academic honor and as an applied math and biology double major along with a minor in chemistry.
Has executed over $4B in transactions including acquisitions, joint ventures and investments in successful businesses including The Geek Squad, Magnolia Audio Video, Pacific Sales, Future Shop Canada, Netflix, Virgin Mobile, Lucky Vitamin.com and others. Christian was CFO for Best Buy Mobile (a $700M business which more than doubled in size during his tenure) and EIR for Best Buy Secondary Markets (a $3B business which optimized the disposal of distressed assets). Christian has a degree in marketing from The University of Colorado in Boulder, CO and an MBA from The Daniels College of Business at the University of Denver in Denver, CO.
Principal Research Scientist in the Bio/Nano/Programmable Matter group at Autodesk. His research focuses on molecular design and chemical space exploration and optimization. Before joining Autodesk, Aaron was a postdoc at Duke University in the Theoretical Chemistry groups. While at Duke, he also developed a quantum theory of molecular pathways for Dexter-type energy transfer.Aaron received his PhD in Physics from the University of Illinois, where he worked with Dr. Todd Martínez to develop methods for simulating and analyzing light-activated chemical dynamics using mixed classical/quantum (QM/MM) models.
We are scaling rapidly and welcome employment applications from experts based all over the world. Please let us know how you can add value to Everyday Pharma by emailing email@example.com